RxDoctor Payments Data

Patrick Romeus, MD

Internal Medicine · Miami, FLNPI 1669464335

Payments from drug & device makers

$3,043in general payments, 2019–2025

Across 147 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$952
  • Bayer$258
  • AstraZeneca$222
  • Otsuka America Pharmaceutical, Inc.$179
  • Amgen$161
  • Novartis$158
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,043100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,043 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$50,047
Medicare patients
70
Services billed
448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala37$144,836
EliquisApixaban229$126,761
JanuviaSitagliptin Phosphate81$102,188
FarxigaDapagliflozin Propanediol82$90,540
OzempicSemaglutide60$77,078
JanumetSitagliptin Phos/Metformin Hcl87$71,619
XareltoRivaroxaban66$69,630
EntrestoSacubitril/Valsartan48$58,422
JardianceEmpagliflozin55$46,943
AptiomEslicarbazepine Acetate50$39,435
InvokanaCanagliflozin41$35,262
DescovyEmtricitabine/Tenofov Alafenam12$27,854
TrulicityDulaglutide27$25,349
TradjentaLinagliptin33$21,590
MounjaroTirzepatide21$21,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$29$172,69049 claims
PfizerEliquis$97$126,761229 claims
Johnson & JohnsonXarelto, Invokana$57$104,892107 claims
AstraZenecaFarxiga, Symbicort$222$96,335109 claims
Novo NordiskOzempic, Fiasp$122$80,53271 claims
NovartisEntresto$158$58,42248 claims
Lilly USA, LLCTrulicity, Mounjaro$100$46,47948 claims
Sunovion Pharmaceuticals Inc.Aptiom$952$39,43550 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →